ATRX Rabbit Polyclonal Antibody
Specialties: Neuropathology
Diffuse gliomas are classified based on histological and molecular features to achieve an integrated diagnosis. Molecular diagnostic markers include IDH mutation, 1p/19q co-deletion, and TP53 mutation. ATRX is a chromatin remodeling protein and its mutation status may be used as a molecular diagnostic marker within the diffuse glioma classification algorithm. Anti-ATRX is used to identify mutant ATRX by a loss of ATRX expression in neoplastic cells when compared with internal positive controls (endothelial cells, glia, and neurons). Grade II/III astrocytoma classification includes IDH mutant, ATRX mutant, and 1p/19q retention, while grade II/III oligodendroglioma includes IDH mutant, ATRX wildtype, and 1p/19q co-deletion; p53 expression may also serve as an aid in diagnosis. ATRX mutation is frequently, but not always, mutually exclusive with 1p/19q co-deletion.1-6
- Cancer Genome Atlas Research Network. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015 Jun 25;372(26):2481-98.
- Reuss DE, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2015 Jan;129(1):133-46.
- Louis DN, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20.
- Ikemura M, et al. Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. Histopathology. 2016 Aug;69(2):260-7.
- Yamamichi A, et al. Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion. Brain Tumor Pathol. 2018 Apr;35(2):106-113.
- Wood MD, et al. Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities. Diagn Pathol. 2019 Apr 9;14(1):29.
Specifications
- Reactivity: paraffin
- Control: Astrocytoma (Nuclear); Glioblastoma (Nuclear); Brain (Nuclear); Oligodendroglioma (Nuclear)
- Dilution Range: 1:50-1:50 *
Package Inserts
IFU
- IVD Rev. 0.0 (CMC48511000)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 0.1 mL concentrate | 485A-14 |
| 0.5 mL concentrate | 485A-15 |
| 1.0 mL concentrate | 485A-16 |
| 1.0 mL predilute ready-to-use | 485A-17 |
| 7.0 mL predilute ready-to-use | 485A-18 |
For research use only (RUO) in Canada
| 0.1 mL concentrate (RUO) | 485A-14-RUO |
| 1.0 mL concentrate (RUO) | 485A-16-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 485A-17-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 485A-18-RUO |
For in vitro diagnostic (IVD) use in Europe
| 0.1 mL concentrate | 485A-14 |
| 0.5 mL concentrate | 485A-15 |
| 1.0 mL concentrate | 485A-16 |
| 1.0 mL predilute ready-to-use | 485A-17 |
| 7.0 mL predilute ready-to-use | 485A-18 |
For research use only (RUO) in Japan
| 0.1 mL concentrate (RUO) | 485A-14-RUO |
| 1.0 mL concentrate (RUO) | 485A-16-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 485A-17-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 485A-18-RUO |
To request information on this product in additional countries, please click the button below.
